Cost Effectiveness of Bevacizumab Plus Chemotherapy for the Treatment of Advanced and Metastatic Cervical Cancer in India-A Model-Based Economic Analysis.
Nidhi GuptaPrerika NehraAkashdeep Singh ChauhanNikita MehraAshish SinghManjunath Nookala KrishnamurthyKavitha RajsekharJayachandran Perumal KalaiyarasiPartha Sarathi RoyPrabhat Singh MalikAnisha MathewPankaj MalhotraAmal Chandra KatakiJyoti DixitSudeep GuptaLalit KumarShankar PrinjaPublished in: JCO global oncology (2022)
Addition of bevacizumab to the standard chemotherapy is not cost effective for the treatment of advanced and metastatic cervical cancer in India at a threshold of 1-time per-capita gross domestic product.